MedPath

Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty

Not Applicable
Completed
Conditions
Fuchs' Endothelial Dystrophy
Registration Number
NCT05399095
Lead Sponsor
University Eye Hospital, Freiburg
Brief Summary

This randomized controlled trial evaluates the efficacy and safety of postoperative supine head positioning on graft attachment after Descemet membrane endothelial keratoplasty in patients with Fuchs' endothelial corneal dystrophy (FECD).

Detailed Description

In Descemet membrane endothelial keratoplasty (DMEK), an air or gas bubble is inserted in the anterior chamber of the eye to keep the ultrathin endothelial corneal graft attached to the patients own cornea. Supine positioning is thought to improve attachment by using the tamponade effect of the bubble. At present, it is unclear how long supine positioning is required. Positioning regimens vary between one hour to over one week. In this trial, the investigators will assess if prolonged supine positioning for 5 days improves graft attachment and long-term outcomes compared to supine positioning for 1 day.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Diagnosis of advanced Fuchs' endothelial corneal dystrophy (FECD)
  • Indication for corneal endothelial transplantation (Descemet Membrane Endothelial Keratoplasty - DMEK)
Exclusion Criteria
  • Other corneal diseases (i.e. corneal scars, corneal dystrophies except FECD, corneal inflammation / infection)
  • Regular use of drugs potentially affecting the cornea (i.e. amiodarone, chloroquine, triptan, isotretinoin, use of contact lenses in past four weeks, anesthetic eye drops)
  • Diabetes mellitus with endorgan complications)
  • Lack of fixation during corneal tomography
  • Bedridden

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Graft attachmentAt two weeks after DMEK

Volume of graft detachment, quantified from a trained and validated neural network for image segmentation of anterior segment optical coherence tomography

Secondary Outcome Measures
NameTimeMethod
Safety of supine positioningAt two weeks and 3 months after DMEK

Adverse events (AE) and serious AEs (SAE)

Disability glareAt 3, 12, and 24 months after DMEK

Straylight meter measurement to determine forward scatter in logs straylight parameter

Subjective visual functionAt 3, 12, and 24 months after DMEK

Subjective visual function on a scale from 0 (worse vision) to 10 (best vision) with higher scores meaning better subjective visual function

Visual acuityAt 3, 12, and 24 months after DMEK

Best-corrected visual acuity to determine visual acuity in letters

Graft health: endothelial cell densityAt 3, 12, and 24 months after DMEK

Specular microscopy to determine endothelial cell density

RebubblingAt two weeks and 3 months after DMEK

Number of eyes with secondary injection of air after DMEK

Graft healthAt 12, and 24 months after DMEK

Slit-lamp exam to identify signs of graft rejection

Patient-reported visual disabilityAt 3, 12, and 24 months after DMEK

The Visual Acuity Factor and Glare Factor of the Visual Function and Corneal Health Status (V-FUCHS) instrument. The instrument's scores are Rasch-analysis based scores expressed in logits. Participants with more difficulty have higher or more positive V-FUCHS scores.

Corneal backscatterAt 3, 12, and 24 months after DMEK

Tomography to determine corneal backscatter in scatter units (SU)

Corneal edemaAt 2 weeks and at 3, 12, and 24 months after DMEK

Tomography to determine corneal edema in µm

Trial Locations

Locations (1)

Medical Center - University of Freiburg, Eye Hospital

🇩🇪

Freiburg, Baden-Wuerttemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath